Medical experts have decried the skyrocketing cost and unavailability of diabetes medications in the country. This was even ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

CN Bio, a leading provider of Organ-on-a-chip Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix® Bioavailability assay kit: ...

Insulin production is dominated by the US’s Eli Lilly and Europe’s Sanofi and Novo Nordisk ... but growing over time.” New ...

Sanofi said that Sarclisa, its treatment for plasma cell cancer, was recommended for EU approval by the European Medicines Agency. The agency's Committee for Medicinal Products for Human Use ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

The rise in type 2 diabetes cases globally presents opportunities for growth in the market for GLP-1 drugs like Ozempic and ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.